Concord Biotech Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Concord Biotech has successfully commissioned and commenced production of injectable at its new manufacturing facility (Unit 4) situated at Valthera.

Powered by Capital Market - Live News

Concord Biotech has invested Rs 6.09 crore through subscription to Right issue of shares in CLEAN MAX EVERGLADES (Clean Max) for installation of hybrid renewable energy plant in the State of Gujarat having a wind capacity of 6.6 MW and solar capacity of 3.3 MWp DC for the plant of the Company situated at Dholka.

Investment in 26% equity share capital in Clean Max, renewable energy aligns with the Company's commitment to sustainability and it's focused efforts to address environmental challenges. By transitioning to renewable energy sources, the company will reduce its carbon footprint, contributing to global efforts to combat climate change. Additionally, renewable energy offers long-term financial benefits, including reduction in energy costs. This strategic investment reinforces the Company's commitment to environmental responsibility, ensuring compliance with evolving environmental regulations, and supporting sustainable growth while enhancing operational efficiency.

Powered by Capital Market - Live News

This rebound follows a steep decline of 28.15% over the preceding seven trading sessions, triggered by the company's disappointing third-quarter financial results for the 2025 fiscal year (Q3FY25).

The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25. Profit before tax (PBT) fell 2% YoY to Rs 75.92 crore during the quarter.

EBITDA stood at Rs 98 crore, registering de-growth of 8% compared with Rs 105.9 crore in corresponding quarter last year. EBITDA margin reduced by 390 bps to 40.1% in Q3 FY25 as against 44% in Q3 FY24.

Concord Biotech is a R&D driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It has a presence in more than 70 countries worldwide.

Powered by Capital Market - Live News

Concord Biotech has invested Rs 6.09 crore through subscription to Right issue of shares in CLEAN MAX EVERGLADES (Clean Max) for installation of hybrid renewable energy plant in the State of Gujarat having a wind capacity of 6.6 MW and solar capacity of 3.3 MWp DC for the plant of the Company situated at Dholka.

Investment in 26% equity share capital in Clean Max, renewable energy aligns with the Company's commitment to sustainability and it's focused efforts to address environmental challenges. By transitioning to renewable energy sources, the company will reduce its carbon footprint, contributing to global efforts to combat climate change. Additionally, renewable energy offers long-term financial benefits, including reduction in energy costs. This strategic investment reinforces the Company's commitment to environmental responsibility, ensuring compliance with evolving environmental regulations, and supporting sustainable growth while enhancing operational efficiency.

Powered by Capital Market - Live News

This rebound follows a steep decline of 28.15% over the preceding seven trading sessions, triggered by the company's disappointing third-quarter financial results for the 2025 fiscal year (Q3FY25).

The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25. Profit before tax (PBT) fell 2% YoY to Rs 75.92 crore during the quarter.

EBITDA stood at Rs 98 crore, registering de-growth of 8% compared with Rs 105.9 crore in corresponding quarter last year. EBITDA margin reduced by 390 bps to 40.1% in Q3 FY25 as against 44% in Q3 FY24.

Concord Biotech is a R&D driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It has a presence in more than 70 countries worldwide.

Powered by Capital Market - Live News

Senco Gold Ltd, Deepak Nitrite Ltd, MSTC Ltd and Orchid Pharma Ltd are among the other losers in the BSE's 'A' group today, 14 February 2025.

Concord Biotech Ltd lost 20.00% to Rs 1688 at 14:48 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 47914 shares were traded on the counter so far as against the average daily volumes of 4439 shares in the past one month.

Senco Gold Ltd crashed 19.99% to Rs 357.6. The stock was the second biggest loser in 'A' group.On the BSE, 1.77 lakh shares were traded on the counter so far as against the average daily volumes of 41073 shares in the past one month.

Deepak Nitrite Ltd tumbled 14.60% to Rs 1910.2. The stock was the third biggest loser in 'A' group.On the BSE, 2.44 lakh shares were traded on the counter so far as against the average daily volumes of 6902 shares in the past one month.

MSTC Ltd dropped 10.92% to Rs 535.35. The stock was the fourth biggest loser in 'A' group.On the BSE, 39461 shares were traded on the counter so far as against the average daily volumes of 18976 shares in the past one month.

Orchid Pharma Ltd plummeted 10.00% to Rs 945.45. The stock was the fifth biggest loser in 'A' group.On the BSE, 22338 shares were traded on the counter so far as against the average daily volumes of 13301 shares in the past one month.

Powered by Capital Market - Live News

Concord Biotech has successfully commissioned and commenced production of injectable at its new manufacturing facility (Unit 4) situated at Valthera.

Powered by Capital Market - Live News

Concord Biotech has invested Rs 6.09 crore through subscription to Right issue of shares in CLEAN MAX EVERGLADES (Clean Max) for installation of hybrid renewable energy plant in the State of Gujarat having a wind capacity of 6.6 MW and solar capacity of 3.3 MWp DC for the plant of the Company situated at Dholka.

Investment in 26% equity share capital in Clean Max, renewable energy aligns with the Company's commitment to sustainability and it's focused efforts to address environmental challenges. By transitioning to renewable energy sources, the company will reduce its carbon footprint, contributing to global efforts to combat climate change. Additionally, renewable energy offers long-term financial benefits, including reduction in energy costs. This strategic investment reinforces the Company's commitment to environmental responsibility, ensuring compliance with evolving environmental regulations, and supporting sustainable growth while enhancing operational efficiency.

Powered by Capital Market - Live News

This rebound follows a steep decline of 28.15% over the preceding seven trading sessions, triggered by the company's disappointing third-quarter financial results for the 2025 fiscal year (Q3FY25).

The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25. Profit before tax (PBT) fell 2% YoY to Rs 75.92 crore during the quarter.

EBITDA stood at Rs 98 crore, registering de-growth of 8% compared with Rs 105.9 crore in corresponding quarter last year. EBITDA margin reduced by 390 bps to 40.1% in Q3 FY25 as against 44% in Q3 FY24.

Concord Biotech is a R&D driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It has a presence in more than 70 countries worldwide.

Powered by Capital Market - Live News

Concord Biotech has invested Rs 6.09 crore through subscription to Right issue of shares in CLEAN MAX EVERGLADES (Clean Max) for installation of hybrid renewable energy plant in the State of Gujarat having a wind capacity of 6.6 MW and solar capacity of 3.3 MWp DC for the plant of the Company situated at Dholka.

Investment in 26% equity share capital in Clean Max, renewable energy aligns with the Company's commitment to sustainability and it's focused efforts to address environmental challenges. By transitioning to renewable energy sources, the company will reduce its carbon footprint, contributing to global efforts to combat climate change. Additionally, renewable energy offers long-term financial benefits, including reduction in energy costs. This strategic investment reinforces the Company's commitment to environmental responsibility, ensuring compliance with evolving environmental regulations, and supporting sustainable growth while enhancing operational efficiency.

Powered by Capital Market - Live News

This rebound follows a steep decline of 28.15% over the preceding seven trading sessions, triggered by the company's disappointing third-quarter financial results for the 2025 fiscal year (Q3FY25).

The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25. Profit before tax (PBT) fell 2% YoY to Rs 75.92 crore during the quarter.

EBITDA stood at Rs 98 crore, registering de-growth of 8% compared with Rs 105.9 crore in corresponding quarter last year. EBITDA margin reduced by 390 bps to 40.1% in Q3 FY25 as against 44% in Q3 FY24.

Concord Biotech is a R&D driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It has a presence in more than 70 countries worldwide.

Powered by Capital Market - Live News

Senco Gold Ltd, Deepak Nitrite Ltd, MSTC Ltd and Orchid Pharma Ltd are among the other losers in the BSE's 'A' group today, 14 February 2025.

Concord Biotech Ltd lost 20.00% to Rs 1688 at 14:48 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 47914 shares were traded on the counter so far as against the average daily volumes of 4439 shares in the past one month.

Senco Gold Ltd crashed 19.99% to Rs 357.6. The stock was the second biggest loser in 'A' group.On the BSE, 1.77 lakh shares were traded on the counter so far as against the average daily volumes of 41073 shares in the past one month.

Deepak Nitrite Ltd tumbled 14.60% to Rs 1910.2. The stock was the third biggest loser in 'A' group.On the BSE, 2.44 lakh shares were traded on the counter so far as against the average daily volumes of 6902 shares in the past one month.

MSTC Ltd dropped 10.92% to Rs 535.35. The stock was the fourth biggest loser in 'A' group.On the BSE, 39461 shares were traded on the counter so far as against the average daily volumes of 18976 shares in the past one month.

Orchid Pharma Ltd plummeted 10.00% to Rs 945.45. The stock was the fifth biggest loser in 'A' group.On the BSE, 22338 shares were traded on the counter so far as against the average daily volumes of 13301 shares in the past one month.

Powered by Capital Market - Live News